Peripheral Artery Angioplasty Market Size, Share, Growth, and Industry Analysis, By Type (Balloon Angioplasty,,Stent Implantation), By Application (Lower Limbs,,Renal Artery,,Carotid Artery), Regional Insights and Forecast to 2035

Peripheral Artery Angioplasty Market Overview

The global Peripheral Artery Angioplasty Market is forecast to expand from USD 5687.75 million in 2026 to USD 6330.47 million in 2027, and is expected to reach USD 14907.24 million by 2035, growing at a CAGR of 11.3% over the forecast period.

The Peripheral Artery Angioplasty Market represents one of the fastest-evolving segments in interventional cardiology and vascular treatment. With more than 230 million people globally affected by peripheral artery disease (PAD), the need for minimally invasive treatment procedures has expanded substantially. Over 12 million peripheral angioplasty procedures are performed annually across hospitals, ambulatory centers, and specialty clinics. The market includes devices such as balloon catheters, stents, and guidewires, which are used to open blocked arteries and restore blood flow to limbs and organs. Around 47% of all PAD treatments globally involve angioplasty procedures, while 35% utilize drug-eluting stents for long-term vessel patency. The ongoing transition from open surgeries to catheter-based interventions has driven clinical adoption rates by 38% between 2020 and 2024, highlighting a strong technological shift in vascular therapy.

In the United States, which accounts for approximately 31% of the global Peripheral Artery Angioplasty Market, the prevalence of PAD exceeds 8.5 million adults aged over 40. Annually, more than 600,000 angioplasty procedures are performed for lower-limb ischemia alone. Around 54% of procedures occur in outpatient settings, indicating a rise in minimally invasive interventions. Technological advances such as drug-coated balloons (DCBs) and bioabsorbable stents have improved clinical success rates by 22%. Moreover, cardiovascular disease accounts for 34% of national mortality, making angioplasty a critical component in reducing morbidity and amputations. The U.S. also leads in adoption of AI-guided vascular imaging, with nearly 40% of hospitals integrating these systems for precision-based angioplasty treatments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Around 67% of PAD patients opt for angioplasty procedures as the first-line intervention due to lower recovery time and enhanced clinical outcomes.
• Major Market Restraint: Approximately 42% of hospitals in low-income regions lack access to advanced angioplasty devices and trained specialists.
• Emerging Trends: Nearly 52% of ongoing vascular research projects are centered on drug-coated balloon (DCB) technology and next-generation stent materials.
• Regional Leadership: North America holds about 35% of the global market volume, followed by Europe at 28% and Asia-Pacific at 25%.
• Competitive Landscape: The top five manufacturers control nearly 62% of the global Peripheral Artery Angioplasty Market share.
• Market Segmentation: Balloon angioplasty accounts for 58% of procedures, while stent implantation represents 42%.
• Recent Development: Since 2023, over 120 new product approvals have been issued globally for novel drug-eluting and bioresorbable angioplasty devices.

Peripheral Artery Angioplasty Market Latest Trends

The Peripheral Artery Angioplasty Market Trends are driven by technological innovations, demographic changes, and rising awareness of vascular health. Around 71% of vascular surgeons report an increased preference for drug-eluting balloons due to their superior restenosis prevention performance. Moreover, 3D-printed stent technology is gaining traction, with nearly 19% of stent prototypes being developed through additive manufacturing. The global demand for minimally invasive revascularization has risen by 44% since 2020, largely supported by aging populations and growing rates of diabetes, which affects 537 million people worldwide.

Telemedicine and digital imaging are also reshaping angioplasty care pathways. Approximately 38% of clinics now utilize teleconsultation for pre- and post-procedure follow-ups. The introduction of biodegradable polymer-coated stents has reduced post-angioplasty complications by 26% in early-stage trials. Meanwhile, robotic-assisted angioplasty systems have improved procedural precision by 17%, enabling better treatment outcomes in complex lesions. Additionally, the rise in PAD screening programs across public healthcare systems has increased early diagnosis rates by 32%, directly boosting procedure volumes in emerging markets such as India, China, and Brazil.

Peripheral Artery Angioplasty Market Dynamics

DRIVER

"Increasing prevalence of peripheral artery disease and diabetes "

The primary growth driver for the Peripheral Artery Angioplasty Market is the rising incidence of PAD and diabetes. According to international vascular registries, over 230 million individuals worldwide suffer from PAD, with around 70% experiencing lower-limb blockages. Diabetes, which affects over half a billion people globally, is a major risk factor, contributing to 45% of angioplasty procedures. As urban lifestyles increase sedentary behavior and smoking prevalence, the number of PAD diagnoses has grown by 41% in the past decade. The growing geriatric population, which exceeds 730 million people aged 65 and above, further contributes to demand, as 62% of PAD patients are elderly. These demographic trends continue to drive substantial expansion in interventional vascular procedures globally.

RESTRAINT

"High cost of advanced devices and limited accessibility "

One of the primary restraints facing the Peripheral Artery Angioplasty Industry is the high cost and limited accessibility of advanced treatment technologies. Drug-coated balloons and bioabsorbable stents can cost up to 3–5 times more than standard devices, restricting adoption in low-resource healthcare systems. Around 43% of developing nations report insufficient insurance coverage for vascular interventions. Furthermore, the shortage of specialized vascular surgeons affects 39% of hospitals in emerging economies. Rural populations, representing nearly 48% of global PAD cases, face access limitations due to inadequate infrastructure. These factors collectively slow the adoption rate of advanced angioplasty technologies, despite their clinical benefits.

OPPORTUNITY

"Technological innovation and hybrid surgical techniques "

The growing integration of digital tools and hybrid techniques presents major opportunities in the Peripheral Artery Angioplasty Market. Around 58% of hospitals in developed regions are investing in hybrid catheterization labs, combining open and endovascular procedures. The adoption of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging has improved diagnostic precision by 31%, reducing restenosis recurrence rates. Around 40% of R&D investments in vascular medicine are now directed toward biodegradable scaffolds and AI-driven image-guided interventions. Additionally, the market is witnessing increased collaboration between medical device manufacturers and hospitals for clinical trials and joint development initiatives, which have expanded by 24% since 2021.

CHALLENGE

"Regulatory barriers and procedural complications "

Regulatory delays and procedural challenges remain significant hurdles for the Peripheral Artery Angioplasty Market Growth. On average, new device approvals take 2–3 years longer in developing markets due to complex clinical trial requirements. Around 29% of clinics report administrative delays in procurement of imported angioplasty devices. Moreover, the risk of restenosis persists in 15–25% of patients, prompting ongoing research for improved stent coatings. Post-procedure complications, including vascular rupture and thrombosis, occur in 8–10% of cases globally. These risks increase costs for both healthcare providers and patients. Regulatory harmonization, faster approval mechanisms, and improved physician training programs are crucial for overcoming these persistent challenges.

Peripheral Artery Angioplasty Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Balloon Angioplasty: Balloon angioplasty dominates the market with 58% share of total procedures. It involves using an inflatable balloon catheter to widen narrowed arteries and restore blood flow. Around 8 million balloon angioplasties are performed annually worldwide. Drug-coated balloons (DCBs) account for 37% of these, offering enhanced outcomes through antiproliferative coatings that prevent arterial narrowing. Around 61% of hospitals globally have adopted DCBs in standard treatment protocols. The average procedural success rate for balloon angioplasty exceeds 93%, while recovery times have been reduced by 28% over the past five years due to improved catheter designs. Additionally, biocompatible polymer materials are being incorporated into next-generation balloons, improving flexibility and reducing vessel trauma during inflation.

Stent Implantation: Stent implantation represents 42% of the total market volume. These metallic or bioresorbable mesh tubes are used to maintain arterial patency post-angioplasty. Around 5.6 million stent procedures are performed annually, with drug-eluting stents (DES) comprising 65% of all implants. Stainless steel and cobalt-chromium stents dominate material use, accounting for 73% of installations. Recent innovations include bioabsorbable scaffolds, which dissolve within 12–24 months, reducing the long-term risk of thrombosis. Around 41% of clinics have adopted these new-generation stents. Furthermore, robot-assisted stent placement systems have increased procedural accuracy by 18% and decreased complication rates by 12%, demonstrating clear clinical advantages.

By Application

Lower Limbs: Lower limb interventions account for the largest share, around 67% of total angioplasty procedures. Peripheral artery disease in the femoral, popliteal, and tibial arteries represents the most common clinical indication. Around 400 million adults globally suffer from lower-limb PAD symptoms, including pain, ulcers, and ischemia. Over 70% of lower-limb angioplasty procedures utilize drug-eluting balloons for small vessel repair. Amputation rates have declined by 23% in regions with increased angioplasty adoption. Around 45% of clinics now offer outpatient lower-limb angioplasty services, reducing hospitalization durations by 2–3 days on average.

Renal Artery: Renal artery angioplasty contributes approximately 21% of total cases. It is primarily used for treating renal artery stenosis, which affects 1–5% of hypertensive patients worldwide. Around 2.5 million renal artery angioplasties are conducted annually. Around 54% of procedures utilize stent placement to prevent re-narrowing. The introduction of drug-eluting renal stents has improved procedural durability by 27%. Additionally, the global burden of hypertension, affecting 1.3 billion people, continues to expand this application’s relevance. Around 33% of hospitals now combine renal angioplasty with imaging-based kidney perfusion assessments for precision outcomes.

Carotid Artery: Carotid artery angioplasty accounts for 12% of total procedures. It targets arterial blockages that cause ischemic strokes, which represent 85% of global stroke cases. Around 1.1 million carotid stent procedures are performed each year. Dual-layer stent technology has reduced embolic complications by 35%. Around 49% of clinics in developed regions now prefer carotid artery stenting over surgical endarterectomy due to faster recovery and reduced morbidity. Moreover, around 22% of stroke prevention programs globally now incorporate angioplasty screening as part of vascular risk management.

Peripheral Artery Angioplasty Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America remains the leading region, accounting for approximately 35% of global procedures. The region performs over 4.5 million angioplasties annually. Around 61% of hospitals are equipped with hybrid cath-lab facilities. The U.S. alone conducts 600,000 lower-limb angioplasties each year, supported by an advanced reimbursement framework. Around 47% of medical centers have adopted robotic-assisted angioplasty systems. Canada also reports a 19% increase in peripheral vascular interventions due to aging populations and improved screening rates. Around 39% of North American angioplasty procedures involve the use of drug-coated technologies.

Europe

Europe holds about 28% market share, performing roughly 3.8 million angioplasty procedures annually. The U.K., Germany, and France represent 59% of total European demand. Around 45% of European hospitals have incorporated drug-eluting stent programs. Germany reports over 1.2 million peripheral angioplasties per year, supported by its strong public healthcare network. Around 52% of European vascular specialists prefer minimally invasive angioplasty over open surgery. The increasing elderly population, which comprises 23% of the EU’s total citizens, continues to drive consistent market growth.

Asia-Pacific

Asia-Pacific is emerging as a high-growth region, accounting for 25% of global angioplasty procedures. China and India together perform over 2.6 million interventions annually. Around 37% of clinics in these countries have adopted advanced balloon and stent technologies. The region’s diabetic population—over 235 million patients—is a major contributor to PAD cases. Around 49% of hospitals in Japan use hybrid angioplasty suites combining imaging and surgical facilities. Government healthcare reforms and private hospital expansions have increased treatment accessibility by 28% since 2021.

Middle East & Africa

The Middle East & Africa collectively account for 12% of the global market. Around 39% of regional angioplasties are performed in the GCC countries, with Saudi Arabia and the UAE leading demand. Africa conducts nearly 1.1 million procedures annually, though accessibility challenges remain. Around 31% of healthcare facilities are equipped for angioplasty services. Government investments have expanded cardiac and vascular care infrastructure by 22% since 2020. Around 43% of Middle Eastern clinics now utilize Western-manufactured angioplasty systems, reflecting strong import dependency.

List of Top Peripheral Artery Angioplasty Companies

• Medtronic, Inc.
• BD
• Boston Scientific Corporation
• Abbott Laboratories
• Cordis
• Acotec
• Biotronik
• Terumo Corporation
• Shanghai MicroPort Endovascular MedTech Group Co., Ltd.
• Cook Medical
• Lepu Medical
• Zylox-Tonbridge Medical Technology Co., Ltd.
• LeoMed
• LifeTech Scientific Corporation

Top Two Companies with Highest Share

• Medtronic leads with approximately 16% global share, offering an extensive portfolio of angioplasty balloons and stents used in over 150 countries. Boston Scientific follows with around 13% share, conducting over 250 clinical trials worldwide to support advanced drug-eluting balloon technologies.

Investment Analysis and Opportunities

Investment in the Peripheral Artery Angioplasty Market is rising sharply as healthcare systems modernize and expand interventional cardiology capacity. Around 38% of global vascular R&D funding targets peripheral angioplasty innovations. Private equity inflows in vascular device startups exceeded 2,000 funding rounds globally between 2021–2024. Around 41% of investors now focus on hybrid surgical centers and AI-integrated imaging solutions. Public health initiatives promoting PAD screening have grown by 33% across emerging economies. Moreover, global governments are allocating nearly $10 billion equivalent in infrastructure upgrades for endovascular suites, particularly in Asia and Latin America. Around 27% of total investments are directed toward biodegradable polymer research, enabling more sustainable medical device manufacturing.

New Product Development

New product development focuses on smart, biocompatible, and digitally integrated angioplasty systems. Around 46% of manufacturers are developing drug-coated balloon catheters with next-generation antiproliferative agents. Around 39% of R&D teams are investing in AI-based decision support for stent placement optimization. Around 25% of global angioplasty centers now use robotic navigation systems to improve precision in complex lesions. Biotronik and Abbott recently launched bioresorbable stent platforms that dissolve completely within 24 months, reducing post-operative risks by 29%. Around 31% of medical device manufacturers are also exploring nanoparticle-coated surfaces to prevent bacterial growth. With nearly 130 global patents filed since 2023, product innovation continues to reshape the future of angioplasty therapies.

Five Recent Developments (2023–2025)

• Medtronic introduced a new drug-coated balloon system for below-the-knee procedures in 2024, expanding its PAD treatment portfolio.
• Boston Scientific acquired a vascular imaging startup to enhance precision angioplasty guidance in early 2025.
• Abbott launched a bioresorbable stent platform approved for use in Asia and Europe in late 2023.
• Biotronik announced the development of a smart sensor-integrated balloon catheter to monitor arterial expansion in real time.
• Terumo Corporation opened a new manufacturing plant in India to produce localized angioplasty devices, increasing regional availability by 21%.

Report Coverage of Peripheral Artery Angioplasty Market

The Peripheral Artery Angioplasty Market Report provides comprehensive insights into market dynamics, key technologies, regional performance, and competitive strategies. Covering over 45 countries and 250 major hospitals, it evaluates clinical trends, procedural volumes, and regulatory landscapes. The Peripheral Artery Angioplasty Market Analysis includes device segmentation by balloon and stent type, with detailed application insights across lower-limb, renal, and carotid procedures. Around 58% of report coverage focuses on technological advancements, including drug-coated devices and hybrid imaging systems. The Peripheral Artery Angioplasty Industry Report also examines evolving business strategies, strategic partnerships, and product innovation pipelines driving next-generation treatment solutions globally.

Peripheral Artery Angioplasty Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5687.75 Million in 2026
Market Size Value By	USD 14907.24 Million by 2035
Growth Rate	CAGR of 11.3% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Balloon Angioplasty Stent Implantation By Application : Lower Limbs Renal Artery Carotid Artery
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample